Youcare Pharmaceutical Group (688658.SH) Subsidiary Receives FDA Clinical Trial Approval for YKYY013 Injection

Stock News09-22

Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its subsidiary Beijing Youcare Innovation Medical Technology Co., Ltd. (referred to as "Youcare Innovation") recently received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) approving clinical trials of YKYY013 injection for the treatment of chronic hepatitis B virus infection (IND Number: 177486). YKYY013 injection is a chemically synthesized double-stranded siRNA drug conjugated with N-acetylgalactosamine (GalNAc) ligand, independently developed by Youcare Innovation and the company's wholly-owned subsidiary Hangzhou Tianlong Pharmaceutical Co., Ltd. Through RNA interference, it effectively silences messenger RNA (mRNA) transcribed from the hepatitis B virus (HBV) genome, thereby inhibiting the production of hepatitis B pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction, ultimately achieving functional cure of hepatitis B. The clinical application is intended for the treatment of chronic hepatitis B virus infection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126418284?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126418284","market":"other","top_or_hot":-1,"title":"Youcare Pharmaceutical Group (688658.SH) Subsidiary Receives FDA Clinical Trial Approval for YKYY013 Injection","media":"Stock News","content":"<p>Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its subsidiary Beijing Youcare Innovation Medical Technology Co., Ltd. (referred to as \"Youcare Innovation\") recently received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) approving clinical trials of YKYY013 injection for the treatment of chronic hepatitis B virus infection (IND Number: 177486). YKYY013 injection is a chemically synthesized double-stranded siRNA drug conjugated with N-acetylgalactosamine (GalNAc) ligand, independently developed by Youcare Innovation and the company's wholly-owned subsidiary Hangzhou Tianlong Pharmaceutical Co., Ltd. Through RNA interference, it effectively silences messenger RNA (mRNA) transcribed from the hepatitis B virus (HBV) genome, thereby inhibiting the production of hepatitis B pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction, ultimately achieving functional cure of hepatitis B. The clinical application is intended for the treatment of chronic hepatitis B virus infection.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Youcare Pharmaceutical Group (688658.SH) Subsidiary Receives FDA Clinical Trial Approval for YKYY013 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYoucare Pharmaceutical Group (688658.SH) Subsidiary Receives FDA Clinical Trial Approval for YKYY013 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-22 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its subsidiary Beijing Youcare Innovation Medical Technology Co., Ltd. (referred to as \"Youcare Innovation\") recently received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) approving clinical trials of YKYY013 injection for the treatment of chronic hepatitis B virus infection (IND Number: 177486). YKYY013 injection is a chemically synthesized double-stranded siRNA drug conjugated with N-acetylgalactosamine (GalNAc) ligand, independently developed by Youcare Innovation and the company's wholly-owned subsidiary Hangzhou Tianlong Pharmaceutical Co., Ltd. Through RNA interference, it effectively silences messenger RNA (mRNA) transcribed from the hepatitis B virus (HBV) genome, thereby inhibiting the production of hepatitis B pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction, ultimately achieving functional cure of hepatitis B. The clinical application is intended for the treatment of chronic hepatitis B virus infection.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688658","symbol_name":"悦康药业","start_time":0,"source_url":"","article_id":"1126418284","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126418284","pubTimestamp":1758532837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its subsidiary Beijing Youcare Innovation Medical Technology Co., Ltd. (referred to as \"Youcare Innovation\") recently received a Study...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688658":"悦康药业","BK0239":"医药制造"},"translate_title":"优康药业集团（688658.SH）子公司YKYY013注射液获FDA临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688658":1},"content_text":"Youcare Pharmaceutical Group Co.,Ltd. (688658.SH) announced that its subsidiary Beijing Youcare Innovation Medical Technology Co., Ltd. (referred to as \"Youcare Innovation\") recently received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) approving clinical trials of YKYY013 injection for the treatment of chronic hepatitis B virus infection (IND Number: 177486). YKYY013 injection is a chemically synthesized double-stranded siRNA drug conjugated with N-acetylgalactosamine (GalNAc) ligand, independently developed by Youcare Innovation and the company's wholly-owned subsidiary Hangzhou Tianlong Pharmaceutical Co., Ltd. Through RNA interference, it effectively silences messenger RNA (mRNA) transcribed from the hepatitis B virus (HBV) genome, thereby inhibiting the production of hepatitis B pathogenic proteins, suppressing HBV replication, and creating conditions for host immune reconstruction, ultimately achieving functional cure of hepatitis B. The clinical application is intended for the treatment of chronic hepatitis B virus infection.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126418284","isCrawlerRequest":true}